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Abstract
In models of hind-limb ischemia and progressive coronary artery occlusion, angiogenic growth factor proteins and genes expressing
growth factors have been shown to induce the development of collateral vessels and remodeling of existing collaterals. The therapeutic
potential of growth factors in the setting of acute myocardial infarction may be related to non-angiogenic properties of growth factors as
well, and is the focus of this review. Ó 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction An interesting hypothesis is that the development of new
vessels (angiogenesis) or the remodeling of preexisting
Acute myocardial infarction (AMI) is a leading cause of collaterals may form natural bypasses that could compen-
death and disability in the Western World. In the United sate for the occlusion of an epicardial coronary artery,
States, 1.5 million people are hospitalized annually with improving the outcome after AMI.
AMI [1], and AMI is responsible for 25% of all deaths [1]. Several growth factors such as fibroblast growth factors
Moreover, a substantial number of AMI survivors are (FGFs) [10,11]. Vascular Endothelial Growth Factor
significantly disabled; thus, the social costs of this disease (VEGF) [12,13]. and Insulin Growth Factors (IGFs)
are enormous. [14,15] have angiogenic properties. During recent years, a
In the last four decades, substantial advances have been number of experimental studies have suggested that treat-
achieved in the treatment of AMI. Treatment of potentially ment with angiogenic growth factors can promote the
fatal arrhythmias in Coronary Care Units [2], infarct size development of collaterals to ischemic tissue in models of
reduction strategies through the introduction of nitrates [3], progressive coronary occlusion [16–19], and AMI [20–
beta-blockers [4], and surgery [5], and most importantly, 22].
thrombolytic agents [6] and direct PTCA [7] have im- Angiogenic growth factors have been shown to reduce
portantly decreased mortality from AMI. These develop- infarct size and improve left ventricular ejection fraction in
ments have reduced the in-hospital mortality to as low as animal models of AMI [20,23]. The reduction in infarct
3% in selected populations of patients with AMI treated by size was associated with increased vascularity in one
direct PTCA [7]. Despite the impact of these develop- study, suggesting that an angiogenic mechanism was
ments, however, heart failure remains the leading cause of operative in reducing infarct size [20]. Nevertheless, it is
in-hospital morbidity and mortality in AMI patients [8]. counterintuitive to suggest that the development of new
Thus, adjunctive therapies for the limitation of infarct size blood vessels could account for a reduction in infarct size,
could serve to limit heart failure and advance the treatment given the extended time-frame required for vascular
of AMI [9]. growth (days), compared to the limited window of oppor-
tunity for myocardial salvage (hours). In addition to their
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effects on angiogenesis [24] and wound healing [25,26], prognosis. Third, healing of the necrotic area may not be
growth factors have other properties that may have im- adequate if the fibroblasts do not receive adequate meta-
portant effects in the setting of AMI. Some growth factors bolic support. If the healing process is improved, a
have been shown to be NO-dependent vasodilators [27,28], reduction in left ventricular remodeling, aneurysm forma-
and some have been reported to have direct neuroprotec- tion and rupture can be expected. These changes may lead
tive [29] and myoprotective effects [30]. Thus, these to benefit in short and long-term prognosis, as well as
growth factors could importantly affect the evolution, functional class.
healing and remodeling of AMI through their effects on In patients with an AMI, it has been shown that the
systemic hemodynamics and loading conditions, car- extent of preexisting coronary collaterals influences infarct
diomyocyte protection, angiogenesis, collateral develop- size, the amount of viable myocardium, aneurysm forma-
ment, and/or wound healing. tion, and prognosis [41–44]. In patients after AMI, it has
Although there are numerous studies of the effects of been demonstrated angiographically that collateral de-
growth factors in chronic myocardial and limb ischemia velopment occurs mainly in the area of the necrotic tissue
[31–33], the potential role of growth factors in AMI has [45,46]. Moreover, the preservation of LV volumes and
received less attention, and is the subject of this review. function after AMI are related to the residual flow obtained
by reperfusion or by collateral vessels [47]. In the context
of thrombolysis shortly after AMI, the benefits of collateral
2. Collateral vessels in acute myocardial infarction vessels in the salvage of myocardium is well documented
[48–51]. When thrombolysis is not successful, a lower
The de novo formation of new vessels in the adult CPK release and a subsequent improvement in LV function
organism (angiogenesis), as well as the remodeling of can be expected if there is a good collateral network to the
innate collateral vessels (collateral remodeling) are pro- ischemic region [48–50].
cesses that require some time to accomplish. Experiments Despite its well known angiogenic properties [12,13],
in animals suggest that both the enlargement of preexisting and the demonstration of an overexpression of VEGF
collaterals and neovascularization require approximately protein and its receptor after AMI [52,53], there are no
24 h for the first cellular mitosis [34], and about 3 days for published studies on the use of VEGF as a potential
the completion of a functionally relevant collateral circula- therapeutic agent in the context of AMI. The growth
tion [35]. This is confirmed by the finding that collateral factors most intensively studied in AMI are the FGFs and
flow appears to increase rapidly in the following days after IGFs.
coronary occlusion in the dog. Four days after occlusion, During recent years, a number of experimental studies
endocardial and epicardial flow have been shown to have suggested that treatment with angiogenic growth
increase to 50% and 75% of their normal values, respec- factors can promote the development of collaterals to
tively [36]. Ten days after coronary occlusion resting flow ischemic tissue in models of progressive coronary occlu-
to the myocardium beyond the coronary occlusion is sion [16–19], and AMI [20–22].
normal [37].
In humans, initial sprouts are seen 3 days after AMI,
shortly after macrophage invasion and before fibroblast 3. Fibroblast growth factors
proliferation and collagen deposition [38].
Based on this information, therefore, it is difficult to 3.1. Molecular characterization
conceive how either angiogenesis or collateral remodeling
could play a role in infarct size reduction, given that the The FGF family of growth factors is comprised of at
myocyte’s window of viability is limited to a few hours least eighteen distinct, but structurally related, growth
[39]. factors. All members contain a common domain which is
From a theoretical point of view, however, vascular responsible for most of their structural homology. FGF-1
development within the myocardial risk region (formation and FGF-2 are the most widely studied members of the
of new vessels and/or the remodeling of innate collaterals) FGF family.
may be beneficial for several reasons. First, when abundant
collateral vessels are present within the risk region imme- 3.2. Acidic fibroblast growth factor (FGF-1)
diately after the total occlusion of a epicardial vessel, a
substantial reduction or even a prevention of the myocar- FGF-1, also called acidic FGF, is a 140 amino acid
dial necrosis can be observed [40]. Second, the develop- peptide [54]. The three-dimensional structure of FGF-1 has
ment of collateral vessels at the border zone can improve recently been shown [55]. Slightly shorter and longer
local perfusion and therefore, enhance the function of the forms of FGF-1 have also been identified [54]. FGF-1 gene
ischemic but otherwise viable myocardium in the penum- has been cloned and expressed [56]. FGF-1 and FGF-2
bra of the necrotic area. This may improve left ventricular have a 55% amino acid sequence homology. This suggest
function and remodeling, both major determinants of that they both derived from a common ancestral gene [57].
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However, FGF-1 and FGF-2 are formed from two different vasodilator [27], and has been reported to have direct
genes in two different chromosomes, which can be ex- neuroprotective [29] and myoprotective [30] properties.
plained by gene duplicating and evolutionary divergence
[57].
4. Insulin growth factors3.3. Basic fibroblast growth factor (FGF-2)
4.1. CharacteristicsThe peptide of FGF-2 (basic fibroblast growth factor)
has been purified and sequenced, and its gene been cloned Insulin growth factors (IGFs) I and II, also known as
and expressed [58]. Southern blot analysis demonstrates
somatomedins [68], were shown to be survival factors to
that FGF-2 is encoded by a single gene [59]. The single-
motor neurons [69]. IGF-I gene expression in mammals
copy gene for human FGF-2 (FGFB) has been localized on
typically results in multiple mRNA species ranging in size
chromosome 4 [60]. The three-dimensional structure of between 0.7 and 7.6 kb [70]. IGF-I and II are single-chainFGF-2 has been elucidated [55]. polypeptides usually of 7.5 kDa [68]. IGF-I and IGF-II are,A comparison of the FGF-2 human and bovine nucleo-
respectively, 70 and 67-amino acid proteins [68]. IGF-II is
tide and amino acid sequences show a high degree of
thought to play an important role in fetal growth and
conservation. Only two of the 155 amino acids are development. The human IGF-II gene is situated ondifferent, giving an overall amino acid sequence homology
chromosome 11, very close to the insulin gene [71].
of 98.7% [61]. The high degree of protein sequence There is a 62% amino acid homology between IGF-I
conservation suggests a very strong selection pressure for
and IGF-II molecular structures [68].
conservation of function and structure. High concentrations of IGF-I and II show insulin-likeThe final protein is formed by 146 amino acids after
metabolic characteristics in vitro and in vivo [68].
removal of the amino-terminal extension of nine amino These growth factors have an important role in control-
acids [54]. There are no precursors with an extended ling the proliferation, differentiation and metabolic activity
carboxyl terminus because a termination codon directly
of mesodermal cells [68].follows the codon for amino acid 146 [58]. The amino- IGFs can attach not only to binding proteins (IGFBP)
terminal region of FGF-2 has been demonstrated to
that are thought to regulate their biological action andfunction as a nuclear translocation sequence. These res- bioavailability [72], but also to insulin receptors, and typeidues do not specifically interact with the remainder of the 1 or 2 IGF receptors [68].
molecule, and if removed, do not induce a loss of function IGF-I has been shown to be an angiogenic growth factor[62].
as potent as FGF-2 in promoting rabbit corneal angio-Multiple molecular forms of FGF-2 have been reported genesis [73]. Moreover, IGF-I seems to participate in the[63]. These proteins are synthesized from one mRNA healing process [74].
species, and some initiate translation at non-AUG codons
[63]. Human FGF-2 is expressed in four forms: an 18 kDa
(155-amino acid) form generated by initiation at the AUG 4.2. FGFs and acute myocardial infarction
codon, and 22, 22.5 and 24 kDa forms (196, 201, and
210-amino acids) arising from the CUG codons located Franco et al. [23] was the first to report on the effects of
upstream of the conventional AUG start site [63]. The high FGF-2 in AMI. In his cat model, AMI was induced by
molecular forms of FGF-2 contain the complete amino occlusion of the left anterior descending artery (LAD).
acid sequence of the 18 kDa form in addition to NH - FGF-2 (25 mg) was suspended in Sephadex beads and2
terminal extensions of varying lengths. injected directly into the ischemic myocardium, 2 min after
The N-extension of FGF-2 confers a nuclear localization coronary occlusion. The authors claimed that infarct size
signal [64], and increases FGF-2 nuclear localization was reduced with this treatment, and speculated that this
which usually is associated with cell proliferation [65]. effect was mediated by myoprotective effects of FGF-2.
The FGF-2 molecular heterogeneity is further complicated Using a canine proximal LAD ameroid model, Banai et
by the fact that FGF-2 isolated from tissues is sometimes al. [18] reported a 44% incidence of AMI. Three weeks
truncated by enzymatic degradation. For example, FGF-2 after ameroid placement, a sponge saturated with FGF-1
has been found as a 131-amino acid form in the ovary, (1–800 mg) was interposed between a vascular pedicle and
kidney and adrenal tissue, as a 146-amino acid protein in the epicardium in the LAD territory. They reported that
the brain and pituitary, and as a 157-amino acid protein in myocardial perfusion was not significantly increased in
the placenta [66,67]. treated dogs; however, striking vascular smooth muscle
Basic FGF has numerous properties that could come into cell hyperplasia was evident in arterioles and small ar-
play in the setting of AMI. In addition to its effects on teries, exclusively in areas of subendocardial infarction. In
angiogenesis [24] and wound healing [25], basic FGF has some areas smooth muscle cells hyperplasia was extreme,
been shown to be a moderately potent NO-dependent causing occlusion of the vessels. This result probably was
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a consequence of the high local level of the growth factor reducing the risk region in FGF-2-treated animals. Risk
achieved in the myocardial tissue. region was not reported in this study.
Yanagisawa-Miwa et al. [20] administered intracoronary Miyataka et al. [79] administered 300 mg of FGF-2
FGF-2 (10 mg) into the left circumflex coronary artery directly into the myocardium supplied by the LAD just
(LCx), 30 min and 6 h after LAD occlusion in dogs. The before the coronary occlusion in dogs. Myocardial perfu-
LAD occlusion was induced by the delivery of an artificial sion was reported to be enhanced 4 weeks after occlusion
thrombus to a segment of the coronary artery previously in the subendocardial, midmyocardial, and subepicardial
made stenotic by laser thermal injury. One week later, regions in FGF-2-treated animals. However, this difference
there was a reduction in infarct size (5% vs. 20%), a better was only seen when the data was presented as ischemic
LV ejection fraction (94% vs. 45% from baseline), and an zone/normal zone ratio. In absolute terms, there were no
increase in the number of capillaries and arterioles in the difference. There was less necrotic myocardium in the
FGF-2-treated animals, without any significant deleterious ischemic region as well as less fibrosis in the FGF-2-
hemodynamic effects. These authors hypothesized that the treated animals [79]. The authors reported 50% mortality
angiogenic response was the cause of myocardial salvage. in both groups. This may have induced a selection bias
However, this is unlikely, given that the first division of towards dogs with higher values of myocardial perfusion.
endothelial cells requires nearly 24 h after the onset of In this study, both necrosis and fibrosis were reported as
ischemia [75,76] and 2–3 days are required after FGF-2 subjective scores.
administration for the formation of new capillaries [77,78]. In a rabbit model, Hasegawa et al. injected 100 mg of
In dogs, it is known that the necrotic process is almost FGF-2 into the myocardium supplied by the LAD, prior to
completely established after 4 h of ischemia [39]. There- acute occlusion [80]. There was subjectively less fibrosis
fore, it is highly unlikely that the angiogenic effect can and more viable myocardium in the border zone in FGF-
have had any significant role in the reduction of necrosis. treated animals; however, microsphere perfusion within the
Yanagisawa-Miwa et al. [20] did not report the sponta- infarcted area was not enhanced. Interestingly, increased
neous rate of LAD recanalization in the first hours after perfusion was observed in the noninfarcted area of FGF-
AMI. treated rabbits. The reasons for this are unclear.
In another study, Battler et al. [21] induced focal MI in Watanabe et al. [81] induced an AMI in pigs by placing
pigs by embolizing sustained-release beads containing an embolization coil in the distal LAD. Four to five weeks
FGF-2 (0,12 mg/kg) into the distal LAD. Thus, the growth later each animal was injected in eight nearby myocardial
factor was immediately available at sites of focal infarc- points with FGF-2 alone (10 mg), or FGF-2 combined with
tion. Increased vascular number was observed in FGF-2- heparan sulfate, heparin, or beads. From these eight
treated animals at day 14. There was no evidence of injection points four were placed in the normal myocar-
improvement in LV function as evaluated by echocardiog- dium and four at the border zone. FGF-2 angiogenic
raphy. The sizes of the risk regions and zones of necrosis potential was evaluated 4–5 weeks after injection. An
were not reported, but were probably small given that no increased number of vessels was detected, particularly
deaths or arrhythmias occurred in either group, and no after FGF-2 plus heparin treatment. These data are difficult
significant changes in blood pressure were observed in the to interpret because the different treatment regimens were
control group after the induction of AMI. tested in the same animal in adjacent areas of the myocar-
Uchida et al. [22] induced AMI in dogs by embolizing dium. Some of these agents may have had interfering
0.1 ml of inorganic mercury into the LAD. The dogs were actions in adjacent regions.
randomized into four experimental groups: saline; heparin Scheinowitz et al. [82] gave intraperitoneal FGF-2 in
(3 mg), FGF-2 (30 mg) or FGF-2 (30 mg)1heparin (3 rats, starting immediately after AMI, continuing for a
mg). These drugs were administered into the pericardial duration of one week. Six weeks after AMI, LV cavity
cavity through the right atrium using a thin needle-tipped diameter was smaller and wall thickness was larger in
catheter. In this study they did not report the time of FGF-2-treated animals, outside the necrotic zone [82]. In a
administration of the drugs after coronary occlusion. The similar study, the same group reported that intraperitoneal
authors considered this procedure to be relative safe, FGF-2 administration was not associated with changes in
because they did not observe any tamponade, even in dogs left ventricular geometry [83].
that received heparin. One month later, they observed a These studies are summarized in Table 1.
significant reduction in myocardial necrosis and an im-
provement in LV function in FGF-2-treated dogs. This 4.3. FGFs and reperfusion
benefit was even greater in dogs treated with FGF-2 plus
heparin. These changes were correlated with changes in Using an in vitro model Padua et al. [84] demonstrated
vascular number. No deaths were reported. The vasodilat- that FGF-2-perfused hearts (5–20 mg/heart) exhibited
ory properties [27] of FGF-2 may have had a confounding increased resistance to ischemia-reperfusion injury. FGF-
effects on the results. Vasodilatation could have allowed treated hearts also showed improved functional recovery
the mercury to migrate distally in the coronary circulation, after ischemia-reperfusion injury. This study was the first
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Table 1
aStudies of FGF-2 in acute myocardial infarction
Authors Animal Vascular Delivery Dose Necrosis Increased
model bed reduction number of
vessels /
perfusion
Franco et al. [32] Cat LAD IM 25 mg Yes NR
Yanagisawa-Miwa et al. [20] Dog LAD IC 10 mg (2X) Yes Yes
Battler et al. [21] Pig LAD IC 0.12 mg/kg NR Yes
Uchida et al. [22] Dog LAD IPc 30 mg Yes Yes
Miyataka et al. [79] Dog LAD IM 300 mg Yes Yes
Hasegawa et al. [80] Rabbit LAD IM 100 mg Yes Yes
Watanabe et al. [81] Pig LAD IM 10 mg NR Yes
Scheinowitz et al. [82,83] Rat LAD IPt 500 mg NR NR
a IM5Intramyocardial; IC5Intracoronary; IPc5Intrapericardial; IPt5Intraperitoneal.
to demonstrate a cardioprotective effect of FGF-2, similar divided into nine experimental groups. These authors
to that previously reported with neuronal cells [85]. suggested that local intramyocardial infusion of FGF-1
Using a canine model in which 4-h mid-LAD occlusion (0,5 mg/ml, 20 ml /min) and/or FGF-2 (2 mg/ml), 60 min
was followed by reperfusion, Horrigan et al. [86] demon- before the occlusion of the LAD was associated with a
strated reduction in infarct size in FGF-2-treated animals protection similar to that obtained by ischemic precondi-
(10 mg infused intracoronary twice, 109 after occlusion, tioning. This effect was receptor-mediated and also re-
and just before reperfusion). FGF-2 treatment was not quired the mitogenic portion of the FGF molecule [89].
associated with beneficial effects on ejection fraction, Moreover, FGF-1 and FGF-2 administration did not pre-
hemodynamic improvement, or evidence of neovasculari- vent cell necrosis, but only delayed the process doubling
zation. Several unexpected findings were reported in this the time necessary for complete infarction.
study. The necrotic area (expressed as a percentage of the These studies are summarized in Table 2.
risk region) in the control group was particularly low
(28%) 4 h after occlusion. (Usually between 75–90% of 4.4. IGFs and acute myocardial infarction
the myocardial tissue inside the risk region is necrotic 3 h
after coronary occlusion [39]). No coronary vasodilatory In patients with AMI, increased IGF-1 levels have been
effects were found after the intracoronary administration of associated with improved left ventricular remodeling and
up to 100 mg of FGF-2. This is in contradistinction to function [90]. Based on experimental animal studies,
another report that showed that FGF-2 is a coronary however, the role of IGF-1 in myocardial remodeling is
vasodilator in dogs [24]. less clear. Using a transgenic mouse model overexpressing
In addition to necrosis, a number of myocytes undergo IGF-1B in cardiac myocytes, Li et al. [91] demonstrated
apoptosis during ischemia-reperfusion injury. In post-mor- that constitutive expression of IGF-1 prevented necrosis of
tem studies in humans that died shortly after AMI, viable myocardium after AMI, reducing ventricular dila-
apoptotic myocytes were frequently found after successful tion and improving myocardial loading and hypertrophy.
thrombolysis [87]. Cuevas et al. [88] suggested in rats (20 In a study in which IGF-1 protein was administered to rats
min of ischemia124 h of reperfusion) that the apoptotic with AMI, there was no apparent effect on left ventricular
process triggered by ischemia-reperfusion injury is reduced geometry [83].
after FGF-1 administration (both native FGF-1 and a There are also suggestions that IGF-2 may improve
non-mitogenic isoform), shortly after the induction of the regional cardiac function by inducing regional myocardial
ischemia [88]. hypertrophy in peri-infarct areas [92]. In a recent study,
Htun et al. [89] studied the effects of FGF-1 and FGF-2 severely dysfunctional myocardium (after MI) was found
in pigs subjected to LAD occlusion for 45, 60 or 90 min, to undergo additional hypertrophy and functional improve-
followed by 120 min of reperfusion. These animals were ment in response to IGF-1 [93].
Table 2
Studies of FGFs in coronary occlusion/ reperfusion
Authors Animal model Vascular bed Delivery Dose Necrosis reduction
Padua et al. [84] Rat Global Perfusate (in vitro) 5–20 mg Yes
Horrigan et al. [86] Dog LAD Intracoronary 10 mg (2X) Yes
Htun et al. [89] Pig LAD Intramyocardial 2 mg/ml No
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4.5. IGFs and reperfusion tial collateralization of the border zone occurs within a few
days after coronary occlusion [35]. Such collaterals will
Insulin growth factor I (IGF-I) as well as IGFBP-3, allow the vital dyes to penetrate much further into the risk
IGFBP-5 and IGFBP-6, seem to participate in inflam- region than at time zero, resulting in underestimation of the
mation-linked angiogenesis and/or tissue repair [14,15]. risk region.
Insulin growth factor II (IGF-II) and IGFBP-5 (which Macroscopic measurement of infarct size
interferes with IGF action, decreasing its function) are [20,22,23,86,89,95] may also be a source of error. Al-
upregulated by ischemia-reperfusion and also by surgical though less expensive and labor intensive, positive staining
stress. IGFBP-5 appears 30 min after IGF [94], a period of with tetrazolium is not synonymous of myocyte viability
time coincident with the ‘‘window’’ in which the myocar- [97]. Moreover, macroscopic analysis is not able to
dium is protected by preconditioning. identify the complex microscopic interdigitations between
Vogt et al. [95] used a pig coronary occlusion model infarcted and normal myocardium [97].
followed by 120 min of reperfusion. Using this model, the In some of the reviewed studies, the number of myocar-
intramyocardial injection of IGF-II (0,25 mg/ml, over 60 dial vessels was assessed in the absence of perfusion-
min) delayed the onset of MI. This effect is similar to that fixation [20–22]. Under these circumstances, many vessels
of insulin administration, which results from insulin re- may be missed.
ceptor activation and is prevented by IGFBP-5 and laven- In one study [21], heparin was administered with the
dustin A, a tyrosine kinase protein inhibitor. growth factor. Heparin is a known angiogenic factor [98–
In a rat model of myocardial ischemia (20 min) and 100], and may have influenced the final result in this
reperfusion (24 h), Buerke et al. [96] demonstrated that particular study. Heparin can be indirectly angiogenic by
1–10 mg IGF-I given 1 h before coronary occlusion was inducing the liberation of growth factors from the extracel-
associated with decreased necrosis as evidenced by lular matrix [101], preventing the inactivation of growth
creatine kinase loss and neutrophil accumulation in the factors [102] and increasing half-life [103], and by poten-
ischemic area. IGF-I also decreased the incidence of tiating the mitogenic activity of growth factors [104].
myocyte apoptosis in this model [96]. In two studies [22,81], the statistical results were not
Bonferroni corrected, overestimating the level of signifi-
cance obtained.
5. Study limitations
In all AMI studies analyzed in this review, coronary 6. Future research directions
occlusion was induced in unconscious animals. The pres-
ence of anesthesia and, in particular, the surgical prepara- Our understanding of the role of angiogenic growth
tion of these animals, create many problems that im- factors on AMI is still in its infancy. More studies are
portantly confound the interpretation of the studies [97]. needed to further clarify the role FGFs and IGFs on
Anesthetics may have major effects on arterial and venous myocardial protection, remodeling, healing, and angio-
tone, determinants of LV loading conditions. The effects of genesis. Study of the potential roles of additional growth
anesthetics on BP, heart rate and contractility have im- factors such as VEGF, TGFs, angiogenin, and HGF in the
portant effects on myocardial oxygen demand. Anesthetics AMI setting is also warranted.
and invasive surgery have profound effects on autonomic
tone, which impacts on many determinants of infarct size.
Some of the reviewed studies did not report infarct size
as a percentage of the risk region [20,22,23,79,89]. The 7. Conclusions
major determinants of infarct size are risk region size,
followed by myocardial perfusion to the ischemic region, In conclusion, published data suggest that FGFs and
and rate–pressure product [97]. Risk region is a critical IGFs may modestly reduce infarct size after AMI. It is
baseline characteristic that is dependent on anatomical unclear whether these effects are due to direct support of
considerations. Therefore, the baseline assessment of risk angiogenesis, myocyte protection, salutary hemodynamic
region size, as well as the presentation of the infarct size as changes, or effects on apoptosis. The studies are generally
a percentage of the risk region, is fundamentally important limited in size, and in many cases technical factors
for accurate comparisons of the efficacy of agents for obfuscate appropriate interpretation of the results. The
infarct size reduction [97]. effects of various growth factors in AMI should not be
Measurement of risk region with vital dyes several days generalized across agents, and the effects of a specific
after coronary occlusion can be associated with a signifi- agent in the setting of AMI may differ significantly from
cant error [86]. Because collateral development occurs its effect in occlusion / reperfusion. Additional studies in
naturally after coronary occlusion, it is likely that substan- this field are warranted.
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